Joseph Gao

发表

Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design

T. Wigal, M. Gasior, M. Brams, 2010, Behavioral and Brain Functions.

Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder

L. Adler, R. Weisler, Joseph Gao, 2009, CNS Spectrums.

Effects of Open-Label Lisdexamfetamine Dimesylate on Self-Reported Quality of Life in Adults with ADHD

T. Wigal, M. Gasior, M. Brams, 2011, Postgraduate medicine.

Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis.

S. Spruance, K. Hamed, M. Conant, 2006, Journal of the American Academy of Dermatology.

Effect Size of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder

T. Wigal, M. Gasior, M. Brams, 2011, Postgraduate medicine.

efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit / hyperactivity disorder : novel findings using a simulated adult workplace environment design Permalink

T. Wigal, M. Gasior, M. Brams, 2010 .

Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial.

F. Aoki, S. Tyring, K. Hamed, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases

H. Nasrallah, J. Lindenmayer, Joseph Gao, 2013, Neuropsychopharmacology.

Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial.

S. McElroy, D. Wilfley, James E Mitchell, 2015, JAMA psychiatry.

Open-Label Administration of Lisdexamfetamine Dimesylate Improves Executive Function Impairments and Symptoms of Attention-Deficit/Hyperactivity Disorder in Adults

T. Brown, M. Gasior, M. Brams, 2010, Postgraduate medicine.

Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.

R. Findling, Joseph Gao, L. Ginsberg, 2009, Journal of child and adolescent psychopharmacology.

Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial.

S. McElroy, D. Wilfley, James E Mitchell, 2015, JAMA psychiatry.

A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.

M. Trivedi, A. Patkar, Joseph Gao, 2013, The Journal of clinical psychiatry.

Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.

R. Findling, Thomas Babcock, A. Turgay, 2010, Journal of child and adolescent psychopharmacology.

Maintenance of Wakefulness With Lisdexamfetamine Dimesylate, Compared With Placebo and Armodafinil in Healthy Adult Males Undergoing Acute Sleep Loss

T. Roth, G. Zammit, M. Gasior, 2014, Journal of clinical psychopharmacology.

Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

J. Newcorn, A. Hervás, M. Huss, 2019, European Neuropsychopharmacology.

Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial.

S. McElroy, D. Wilfley, James E Mitchell, 2015, JAMA psychiatry.

Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.

R. McIntyre, O. Brawman‐Mintzer, R. Weisler, 2016, Journal of affective disorders.

Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.

R. Findling, Joseph Gao, L. Ginsberg, 2009, Journal of child and adolescent psychopharmacology.